波纳提尼布诱导的肺炎与严重的急性呼吸紧张综合征
相关实验视频
Updated: Jul 8, 2025
09:49
Experimental Model to Evaluate Resolution of Pneumonia
Published on: February 17, 2023
1.3K
Sofia Dinis Ferreira1, Margarida Jardim1, Margarida Câmara1
1Serviço de Medicina Intensiva, Hospital Dr. Nélio Mendonça, Funchal, Portugal.
European journal of case reports in internal medicine
|December 11, 2023
概括
波纳替尼是费城染色体阳性急性淋巴细胞白血病的氨酸激酶抑制剂,可引起罕见但严重的肺部并发症. 及时的类固醇治疗以及药物调整可以有效地管理这种毒性.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
背景情况:
- 波纳替尼是第三代氨酸激酶抑制剂 (TKI),用于费城染色体阳性急性淋巴细胞白血病 (Ph+ALL),特别是在耐药病例中.
- 包括ponatinib在内的TKIs的不良事件 (AE) 可能在治疗后期发生,心血管问题是最常见的.
- 肺部并发症是波纳替尼治疗的不太常见但严重的潜在毒性.
研究的目的:
- 在接受ponatinib治疗的患者中报告严重急性呼吸困扰综合征 (ARDS) 的病例.
- 为了突出波纳提尼布诱导的肺毒性的潜力.
- 讨论这种并发症的管理.
主要方法:
- 本文介绍了一个42岁的女性患有Ph+ALL而接受ponatinib治疗的病例报告.
- 患者出现呼吸衰竭和ARDS,最初用抗生素和抗病毒药物治疗,但没有改善.
- 考虑了TKI诱导的肺部并发症的诊断,导致启动类固醇治疗方案.
主要成果:
- 患者经历了呼吸衰竭和ARDS恶化,尽管标准的抗菌药物治疗.
- 在引入类固醇后,患者表现出显著的改善,肺部并发症得到解决.
- 这表明ponatinib和观察到的肺毒性之间存在潜在的联系.
结论:
- 波纳替尼可能很少引起肺毒性,表现为新出现的呼吸不全.
- 治疗包括调整或停止波纳替尼和开始类固醇治疗.
- 在治疗期间,临床医生应考虑在患有无法解释的呼吸衰竭的患者中考虑波纳替尼诱导的肺毒性.
相关概念视频
01:27Pneumothorax-II
156
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
156
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
174
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
187
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
187
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170
01:21Acute Respiratory Failure-II
239
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
239
01:28Pneumonia IV: Management
333
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
333